AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: A preliminary study

Ali M. Rad, A. S.M. Iskander, Branislava Janic, Robert A. Knight, Ali Syed Arbab, Hamid Soltanian-Zadeh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Despite enormous progress in gene therapy for breast cancer, an optimal systemic vehicle for delivering gene products to the target tissue is still lacking. The purpose of this study was to determine whether AC133+ progenitor cells (APC) can be used as both gene delivery vehicles and cellular probes for magnetic resonance imaging (MRI). In this study, we used superparamagentic iron oxide (SPIO)-labeled APCs to carry the human sodium iodide symporter (hNIS) gene to the sites of implanted breast cancer in mouse model. In vivo real time tracking of these cells was performed by MRI and expression of hNIS was determined by Tc-99m pertechnetate (Tc-99m) scan. Results: Three million human breast cancer (MDA-MB-231) cells were subcutaneously implanted in the right flank of nude mice. APCs, isolated from fresh human cord blood, were genetically transformed to carry the hNIS gene using adenoviral vectors and magnetically labeled with ferumoxides-protamine sulfate (FePro) complexes. Magnetically labeled genetically transformed cells were administered intravenously in tumor bearing mice when tumors reached 0.5 cm in the largest dimension. MRI and single photon emission computed tomography (SPECT) images were acquired 3 and 7 days after cell injection, with a 7 Tesla animal MRI system and a custom built micro-SPECT using Tc-99m, respectively. Expression of hNIS in accumulated cells was determined by staining with anti-hNIS antibody. APCs were efficiently labeled with ferumoxide-protamine sulfate (FePro) complexes and transduced with hNIS gene. Our study showed not only the accumulation of intravenously administered genetically transformed, magnetically labeled APCs in the implanted breast cancer, but also the expression of hNIS gene at the tumor site. Tc-99m activity ratio (tumor/non-tumor) was significantly different between animals that received non-transduced and transduced cells (P < 0.001). Conclusion: This study indicates that genetically transformed, magnetically labeled APCs can be used both as delivery vehicles and cellular probes for detecting in vivo migration and homing of cells. Furthermore, they can potentially be used as a gene carrier system for the treatment of tumor or other diseases.

Original languageEnglish (US)
Article number28
JournalBMC Biotechnology
Volume9
DOIs
StatePublished - Mar 27 2009
Externally publishedYes

Fingerprint

Stem Cells
Genes
Neoplasms
Magnetic Resonance Imaging
Breast Neoplasms
Protamines
Single-Photon Emission-Computed Tomography
Cell Tracking
Sodium Pertechnetate Tc 99m
sodium-iodide symporter
Fetal Blood
Nude Mice
Genetic Therapy
Cell Movement
Staining and Labeling
Injections
Antibodies

ASJC Scopus subject areas

  • Biotechnology

Cite this

AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models : A preliminary study. / Rad, Ali M.; Iskander, A. S.M.; Janic, Branislava; Knight, Robert A.; Arbab, Ali Syed; Soltanian-Zadeh, Hamid.

In: BMC Biotechnology, Vol. 9, 28, 27.03.2009.

Research output: Contribution to journalArticle

Rad, Ali M. ; Iskander, A. S.M. ; Janic, Branislava ; Knight, Robert A. ; Arbab, Ali Syed ; Soltanian-Zadeh, Hamid. / AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models : A preliminary study. In: BMC Biotechnology. 2009 ; Vol. 9.
@article{6107133868bb4584b6a9f067fa786236,
title = "AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: A preliminary study",
abstract = "Background: Despite enormous progress in gene therapy for breast cancer, an optimal systemic vehicle for delivering gene products to the target tissue is still lacking. The purpose of this study was to determine whether AC133+ progenitor cells (APC) can be used as both gene delivery vehicles and cellular probes for magnetic resonance imaging (MRI). In this study, we used superparamagentic iron oxide (SPIO)-labeled APCs to carry the human sodium iodide symporter (hNIS) gene to the sites of implanted breast cancer in mouse model. In vivo real time tracking of these cells was performed by MRI and expression of hNIS was determined by Tc-99m pertechnetate (Tc-99m) scan. Results: Three million human breast cancer (MDA-MB-231) cells were subcutaneously implanted in the right flank of nude mice. APCs, isolated from fresh human cord blood, were genetically transformed to carry the hNIS gene using adenoviral vectors and magnetically labeled with ferumoxides-protamine sulfate (FePro) complexes. Magnetically labeled genetically transformed cells were administered intravenously in tumor bearing mice when tumors reached 0.5 cm in the largest dimension. MRI and single photon emission computed tomography (SPECT) images were acquired 3 and 7 days after cell injection, with a 7 Tesla animal MRI system and a custom built micro-SPECT using Tc-99m, respectively. Expression of hNIS in accumulated cells was determined by staining with anti-hNIS antibody. APCs were efficiently labeled with ferumoxide-protamine sulfate (FePro) complexes and transduced with hNIS gene. Our study showed not only the accumulation of intravenously administered genetically transformed, magnetically labeled APCs in the implanted breast cancer, but also the expression of hNIS gene at the tumor site. Tc-99m activity ratio (tumor/non-tumor) was significantly different between animals that received non-transduced and transduced cells (P < 0.001). Conclusion: This study indicates that genetically transformed, magnetically labeled APCs can be used both as delivery vehicles and cellular probes for detecting in vivo migration and homing of cells. Furthermore, they can potentially be used as a gene carrier system for the treatment of tumor or other diseases.",
author = "Rad, {Ali M.} and Iskander, {A. S.M.} and Branislava Janic and Knight, {Robert A.} and Arbab, {Ali Syed} and Hamid Soltanian-Zadeh",
year = "2009",
month = "3",
day = "27",
doi = "10.1186/1472-6750-9-28",
language = "English (US)",
volume = "9",
journal = "BMC Biotechnology",
issn = "1472-6750",
publisher = "BioMed Central",

}

TY - JOUR

T1 - AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models

T2 - A preliminary study

AU - Rad, Ali M.

AU - Iskander, A. S.M.

AU - Janic, Branislava

AU - Knight, Robert A.

AU - Arbab, Ali Syed

AU - Soltanian-Zadeh, Hamid

PY - 2009/3/27

Y1 - 2009/3/27

N2 - Background: Despite enormous progress in gene therapy for breast cancer, an optimal systemic vehicle for delivering gene products to the target tissue is still lacking. The purpose of this study was to determine whether AC133+ progenitor cells (APC) can be used as both gene delivery vehicles and cellular probes for magnetic resonance imaging (MRI). In this study, we used superparamagentic iron oxide (SPIO)-labeled APCs to carry the human sodium iodide symporter (hNIS) gene to the sites of implanted breast cancer in mouse model. In vivo real time tracking of these cells was performed by MRI and expression of hNIS was determined by Tc-99m pertechnetate (Tc-99m) scan. Results: Three million human breast cancer (MDA-MB-231) cells were subcutaneously implanted in the right flank of nude mice. APCs, isolated from fresh human cord blood, were genetically transformed to carry the hNIS gene using adenoviral vectors and magnetically labeled with ferumoxides-protamine sulfate (FePro) complexes. Magnetically labeled genetically transformed cells were administered intravenously in tumor bearing mice when tumors reached 0.5 cm in the largest dimension. MRI and single photon emission computed tomography (SPECT) images were acquired 3 and 7 days after cell injection, with a 7 Tesla animal MRI system and a custom built micro-SPECT using Tc-99m, respectively. Expression of hNIS in accumulated cells was determined by staining with anti-hNIS antibody. APCs were efficiently labeled with ferumoxide-protamine sulfate (FePro) complexes and transduced with hNIS gene. Our study showed not only the accumulation of intravenously administered genetically transformed, magnetically labeled APCs in the implanted breast cancer, but also the expression of hNIS gene at the tumor site. Tc-99m activity ratio (tumor/non-tumor) was significantly different between animals that received non-transduced and transduced cells (P < 0.001). Conclusion: This study indicates that genetically transformed, magnetically labeled APCs can be used both as delivery vehicles and cellular probes for detecting in vivo migration and homing of cells. Furthermore, they can potentially be used as a gene carrier system for the treatment of tumor or other diseases.

AB - Background: Despite enormous progress in gene therapy for breast cancer, an optimal systemic vehicle for delivering gene products to the target tissue is still lacking. The purpose of this study was to determine whether AC133+ progenitor cells (APC) can be used as both gene delivery vehicles and cellular probes for magnetic resonance imaging (MRI). In this study, we used superparamagentic iron oxide (SPIO)-labeled APCs to carry the human sodium iodide symporter (hNIS) gene to the sites of implanted breast cancer in mouse model. In vivo real time tracking of these cells was performed by MRI and expression of hNIS was determined by Tc-99m pertechnetate (Tc-99m) scan. Results: Three million human breast cancer (MDA-MB-231) cells were subcutaneously implanted in the right flank of nude mice. APCs, isolated from fresh human cord blood, were genetically transformed to carry the hNIS gene using adenoviral vectors and magnetically labeled with ferumoxides-protamine sulfate (FePro) complexes. Magnetically labeled genetically transformed cells were administered intravenously in tumor bearing mice when tumors reached 0.5 cm in the largest dimension. MRI and single photon emission computed tomography (SPECT) images were acquired 3 and 7 days after cell injection, with a 7 Tesla animal MRI system and a custom built micro-SPECT using Tc-99m, respectively. Expression of hNIS in accumulated cells was determined by staining with anti-hNIS antibody. APCs were efficiently labeled with ferumoxide-protamine sulfate (FePro) complexes and transduced with hNIS gene. Our study showed not only the accumulation of intravenously administered genetically transformed, magnetically labeled APCs in the implanted breast cancer, but also the expression of hNIS gene at the tumor site. Tc-99m activity ratio (tumor/non-tumor) was significantly different between animals that received non-transduced and transduced cells (P < 0.001). Conclusion: This study indicates that genetically transformed, magnetically labeled APCs can be used both as delivery vehicles and cellular probes for detecting in vivo migration and homing of cells. Furthermore, they can potentially be used as a gene carrier system for the treatment of tumor or other diseases.

UR - http://www.scopus.com/inward/record.url?scp=64849105492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849105492&partnerID=8YFLogxK

U2 - 10.1186/1472-6750-9-28

DO - 10.1186/1472-6750-9-28

M3 - Article

C2 - 19327159

AN - SCOPUS:64849105492

VL - 9

JO - BMC Biotechnology

JF - BMC Biotechnology

SN - 1472-6750

M1 - 28

ER -